Carrie Donohoe

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial

Lise J Estcourt, Zoe McQuilten, Peter Bardy, Merrole Cole‐Sinclair et autres

Building regional clinical trial capacity and identifying unmet needs: 10-year audit of medical oncology clinic trials activated at the Sunshine Coast University Hospital and Health Service (SCHHS)

Betty Y Zhang, Carrie Donohoe, Christelle Catuogno, Cassie Turner et autres

Background: Clinical trials are routinely recommended as gold standard treatment options by most cancer guidelines. Ensuring equity of access to trials in regional and remote health services is an important quality indicator of cancer services delivery in regional Queensland. Thus, identification of …

A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of a first in class Pol1 inhibitor (CX-5461) in Patients with Advanced Haematologic Malignancies (HM)

Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein et autres

au (code pays fourni par la source)

A phase 1, open-label, dose escalation, safety, PK and PD study of a first in class Pol1 inhibitor (CX-5461) in patients with advanced hematologic malignancies (HM).

Simon J. Harrison, Amit Khot, Natalie Brajanovski, Donald P. Cameron et autres

e22212 Background: Ribosome biogenesis driven by RNA polymerase 1 (Pol1) is a fundamental cellular process increased in malignancy. We have shown that CX-5461, a small molecule inhibitor of Pol1, selectively targets AML, lymphoma and myeloma cells in preclinical in-vivomodels with minimal effects …

au (code pays fourni par la source)